HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy.
Khiyam HussainRena LiuRosanna C G SmithKri T J MüllerMohammadmersad GhorbaniSofia MacariKirstie L S ClearyRobert J OldhamRussell B FoxallSonya JamesSteven G BoothTom MurrayLekh N DahalChantal E HargreavesRobert S KempJemma LongleyJames DouglasHannah MarkhamSerena J CheeRichard J StopforthAli RoghanianMatthew J CarterChristian H OttensmeierBjorn FrendéusRamsey I CutressRuth R FrenchMartin J GlennieJonathan C StreffordStephen M ThirdboroughStephen A BeersMark S CraggPublished in: Journal of experimental & clinical cancer research : CR (2022)
Our findings provide a detailed molecular and cellular basis for hypoxia driven resistance to antitumor mAb immunotherapy, unveiling a hitherto unexplored aspect of the TME. These findings provide a mechanistic rationale for the modulation of FcγRIIb expression or its blockade as a promising strategy to enhance approved and novel mAb immunotherapies.